Characteristics for all Adult Hospitalized COVID-19 Patients by Anticoagulation Status
| Characteristic . | Overall . | No Anticoagulation . | Prophylaxis . | Therapeutic . |
|---|---|---|---|---|
| Total population, No. | 162 842 | 58 675 | 65 256 | 38 911 |
| Demographics | ||||
| Age, y, mean (SD) | 56 (19) | 49 (20) | 58 (18) | 61 (17) |
| Male sex | 79 401 (49) | 24 895 (42) | 32 532 (50) | 21 974 (56) |
| Race and ethnicitya | ||||
| Asian | 5356 (3.5) | 1706 (3.1) | 2412 (3.9) | 1238 (3.4) |
| Hispanic or Latino | 33 713 (22) | 12 076 (22) | 13 785 (22) | 7852 (22) |
| Native Hawaiian or other Pacific Islander | 251 (0.2) | 88 (0.2) | 116 (0.2) | 47 (0.1) |
| Non-Hispanic black | 36 957 (24) | 14 933 (27) | 13 074 (21) | 8950 (25) |
| Non-Hispanic white | 75 948 (50) | 25 775 (47) | 31 974 (52) | 18 199 (50) |
| Other | 880 (0.6) | 303 (0.6) | 362 (0.6) | 215 (0.6) |
| Regionb | ||||
| Midwest | 47 430 (35) | 17 136 (36) | 19 348 (37) | 10 946 (32) |
| Northeast | 33 278 (25) | 11 242 (23) | 12 407 (24) | 9629 (28) |
| South | 36 797 (27) | 14 715 (31) | 13 083 (25) | 8999 (26) |
| West | 17 557 (13) | 5087 (11) | 7902 (15) | 4568 (13) |
| Length of stay, d, mean (SD) | 9 (13) | 5 (9) | 9 (12) | 13 (16) |
| Comorbidities | ||||
| BMI, kg/m2, mean (SD)c | 31 (9) | 30 (8) | 31 (9) | 32 (9) |
| Charlson Comorbidity Index, mean (SD) | 1 (2) | 1 (2) | 1 (2) | 1 (2) |
| Cancer | 10 733 (6.6) | 3563 (6.1) | 4488 (6.9) | 2682 (6.9) |
| Chronic pulmonary disease | 21 046 (13) | 6972 (12) | 9247 (14) | 4827 (12) |
| Congestive heart failure | 9455 (5.8) | 2842 (4.8) | 3893 (6.0) | 2720 (7.0) |
| Dementia | 3527 (2.2) | 896 (1.5) | 1865 (2.9) | 766 (2.0) |
| Diabetes mellitus with complications | 11 884 (7.3) | 3573 (6.1) | 5269 (8.1) | 3042 (7.8) |
| Diabetes mellitus | 27 760 (17) | 7910 (13) | 12 711 (19) | 7139 (18) |
| HIV | 830 (0.5) | 348 (0.6) | 339 (0.5) | 143 (0.4) |
| Liver disease, mild | 7790 (4.8) | 2830 (4.8) | 3366 (5.2) | 1594 (4.1) |
| Liver disease, severe | 1384 (0.8) | 620 (1.1) | 523 (0.8) | 241 (0.6) |
| Metastases | 2281 (1.4) | 770 (1.3) | 909 (1.4) | 602 (1.5) |
| Myocardial infarction | 4615 (2.8) | 1282 (2.2) | 2096 (3.2) | 1237 (3.2) |
| Paralysis | 849 (0.5) | 258 (0.4) | 401 (0.6) | 190 (0.5) |
| Peptic ulcer disease | 1544 (0.9) | 571 (1.0) | 663 (1.0) | 310 (0.8) |
| Peripheral vascular disease | 8580 (5.3) | 2686 (4.6) | 3674 (5.6) | 2220 (5.7) |
| Renal disease | 13 898 (8.5) | 4815 (8.2) | 5630 (8.6) | 3453 (8.9) |
| Rheumatologic disease | 4836 (3.0) | 1511 (2.6) | 2179 (3.3) | 1146 (2.9) |
| Laboratory tests, mean (SD) | ||||
| CBC | ||||
| Hemoglobin, g/dL | 13.04 (2.21) | 12.69 (2.32) | 13.23 (2.10) | 13.17 (2.20) |
| MCV, fL | 88 (7) | 88 (7) | 88 (7) | 89 (7) |
| Platelet count, ×10E3/µL | 229 (97) | 229 (95) | 228 (96) | 232 (100) |
| Neutrophils, absolute, ×10E3/µL | 88 (7) | 88 (7) | 88 (7) | 89 (7) |
| Lymphocytes, absolute, ×10E3/µL | 1.91 (1.54) | 2.06 (2.10) | 1.76 (1.22) | 2.02 (1.47) |
| CMP | ||||
| Glucose, mg/dL | 147 (78) | 135 (74) | 148 (77) | 158 (84) |
| BUN, mg/dL | 21 (19) | 22 (22) | 20 (17) | 24 (20) |
| Creatinine, mg/dL | 1.34 (1.67) | 1.50 (2.09) | 1.22 (1.38) | 1.37 (1.54) |
| BUN/creatinine ratio | 18 (9) | 17 (9) | 18 (8) | 19 (9) |
| Albumin, g/dL | 3.53 (0.61) | 3.65 (0.67) | 3.52 (0.57) | 3.39 (0.57) |
| ALT, SGPT | 50 (163) | 49 (221) | 49 (127) | 52 (140) |
| AST, SGOT | 63 (256) | 62 (327) | 60 (188) | 69 (271) |
| Coagulation | ||||
| D-dimer, mg/L FEU | 2.11 (3.59) | 2.08 (3.90) | 1.85 (3.09) | 2.70 (4.24) |
| International Normalized Ratio | 1.20 (0.62) | 1.29 (0.95) | 1.13 (0.39) | 1.21 (0.58) |
| Fibrinogen, pg/mL | 521 (191) | 441 (188) | 531 (182) | 543 (195) |
| Inflammatory and other | ||||
| ESR, mm/h | 56 (34) | 51 (35) | 56 (33) | 58 (33) |
| IL-6, pg/mL | 96 (876) | 223 (2596) | 75 (239) | 97 (535) |
| LDH, units/L | 454 (586) | 417 (878) | 417 (356) | 533 (692) |
| Lactate, mM | 1.91 (1.54) | 2.06 (2.10) | 1.76 (1.22) | 2.02 (1.47) |
| Characteristic . | Overall . | No Anticoagulation . | Prophylaxis . | Therapeutic . |
|---|---|---|---|---|
| Total population, No. | 162 842 | 58 675 | 65 256 | 38 911 |
| Demographics | ||||
| Age, y, mean (SD) | 56 (19) | 49 (20) | 58 (18) | 61 (17) |
| Male sex | 79 401 (49) | 24 895 (42) | 32 532 (50) | 21 974 (56) |
| Race and ethnicitya | ||||
| Asian | 5356 (3.5) | 1706 (3.1) | 2412 (3.9) | 1238 (3.4) |
| Hispanic or Latino | 33 713 (22) | 12 076 (22) | 13 785 (22) | 7852 (22) |
| Native Hawaiian or other Pacific Islander | 251 (0.2) | 88 (0.2) | 116 (0.2) | 47 (0.1) |
| Non-Hispanic black | 36 957 (24) | 14 933 (27) | 13 074 (21) | 8950 (25) |
| Non-Hispanic white | 75 948 (50) | 25 775 (47) | 31 974 (52) | 18 199 (50) |
| Other | 880 (0.6) | 303 (0.6) | 362 (0.6) | 215 (0.6) |
| Regionb | ||||
| Midwest | 47 430 (35) | 17 136 (36) | 19 348 (37) | 10 946 (32) |
| Northeast | 33 278 (25) | 11 242 (23) | 12 407 (24) | 9629 (28) |
| South | 36 797 (27) | 14 715 (31) | 13 083 (25) | 8999 (26) |
| West | 17 557 (13) | 5087 (11) | 7902 (15) | 4568 (13) |
| Length of stay, d, mean (SD) | 9 (13) | 5 (9) | 9 (12) | 13 (16) |
| Comorbidities | ||||
| BMI, kg/m2, mean (SD)c | 31 (9) | 30 (8) | 31 (9) | 32 (9) |
| Charlson Comorbidity Index, mean (SD) | 1 (2) | 1 (2) | 1 (2) | 1 (2) |
| Cancer | 10 733 (6.6) | 3563 (6.1) | 4488 (6.9) | 2682 (6.9) |
| Chronic pulmonary disease | 21 046 (13) | 6972 (12) | 9247 (14) | 4827 (12) |
| Congestive heart failure | 9455 (5.8) | 2842 (4.8) | 3893 (6.0) | 2720 (7.0) |
| Dementia | 3527 (2.2) | 896 (1.5) | 1865 (2.9) | 766 (2.0) |
| Diabetes mellitus with complications | 11 884 (7.3) | 3573 (6.1) | 5269 (8.1) | 3042 (7.8) |
| Diabetes mellitus | 27 760 (17) | 7910 (13) | 12 711 (19) | 7139 (18) |
| HIV | 830 (0.5) | 348 (0.6) | 339 (0.5) | 143 (0.4) |
| Liver disease, mild | 7790 (4.8) | 2830 (4.8) | 3366 (5.2) | 1594 (4.1) |
| Liver disease, severe | 1384 (0.8) | 620 (1.1) | 523 (0.8) | 241 (0.6) |
| Metastases | 2281 (1.4) | 770 (1.3) | 909 (1.4) | 602 (1.5) |
| Myocardial infarction | 4615 (2.8) | 1282 (2.2) | 2096 (3.2) | 1237 (3.2) |
| Paralysis | 849 (0.5) | 258 (0.4) | 401 (0.6) | 190 (0.5) |
| Peptic ulcer disease | 1544 (0.9) | 571 (1.0) | 663 (1.0) | 310 (0.8) |
| Peripheral vascular disease | 8580 (5.3) | 2686 (4.6) | 3674 (5.6) | 2220 (5.7) |
| Renal disease | 13 898 (8.5) | 4815 (8.2) | 5630 (8.6) | 3453 (8.9) |
| Rheumatologic disease | 4836 (3.0) | 1511 (2.6) | 2179 (3.3) | 1146 (2.9) |
| Laboratory tests, mean (SD) | ||||
| CBC | ||||
| Hemoglobin, g/dL | 13.04 (2.21) | 12.69 (2.32) | 13.23 (2.10) | 13.17 (2.20) |
| MCV, fL | 88 (7) | 88 (7) | 88 (7) | 89 (7) |
| Platelet count, ×10E3/µL | 229 (97) | 229 (95) | 228 (96) | 232 (100) |
| Neutrophils, absolute, ×10E3/µL | 88 (7) | 88 (7) | 88 (7) | 89 (7) |
| Lymphocytes, absolute, ×10E3/µL | 1.91 (1.54) | 2.06 (2.10) | 1.76 (1.22) | 2.02 (1.47) |
| CMP | ||||
| Glucose, mg/dL | 147 (78) | 135 (74) | 148 (77) | 158 (84) |
| BUN, mg/dL | 21 (19) | 22 (22) | 20 (17) | 24 (20) |
| Creatinine, mg/dL | 1.34 (1.67) | 1.50 (2.09) | 1.22 (1.38) | 1.37 (1.54) |
| BUN/creatinine ratio | 18 (9) | 17 (9) | 18 (8) | 19 (9) |
| Albumin, g/dL | 3.53 (0.61) | 3.65 (0.67) | 3.52 (0.57) | 3.39 (0.57) |
| ALT, SGPT | 50 (163) | 49 (221) | 49 (127) | 52 (140) |
| AST, SGOT | 63 (256) | 62 (327) | 60 (188) | 69 (271) |
| Coagulation | ||||
| D-dimer, mg/L FEU | 2.11 (3.59) | 2.08 (3.90) | 1.85 (3.09) | 2.70 (4.24) |
| International Normalized Ratio | 1.20 (0.62) | 1.29 (0.95) | 1.13 (0.39) | 1.21 (0.58) |
| Fibrinogen, pg/mL | 521 (191) | 441 (188) | 531 (182) | 543 (195) |
| Inflammatory and other | ||||
| ESR, mm/h | 56 (34) | 51 (35) | 56 (33) | 58 (33) |
| IL-6, pg/mL | 96 (876) | 223 (2596) | 75 (239) | 97 (535) |
| LDH, units/L | 454 (586) | 417 (878) | 417 (356) | 533 (692) |
| Lactate, mM | 1.91 (1.54) | 2.06 (2.10) | 1.76 (1.22) | 2.02 (1.47) |
Continuous variables presented as mean (standard deviation), as indicated, and categorical variables as frequency, No. (%).
Abbreviations: ALT, SGPT, alanine aminotransferase, serum glutamic-pyruvic transaminase; AST, SGOT, aspartate aminotransferase, serum glutamic-oxaloacetic transaminase; BMI, body mass index; BUN, blood urea nitrogen; CBC, complete blood count; CMP, comprehensive metabolic panel; COVID-19, coronavirus disease 2019; ESR, erythrocyte sedimentation rate; FEU, fibrinogen equivalent unit; HIV, human immunodeficiency virus; IL-6, interleukin 6; LDH, lactate dehydrogenase; MCV, mean corpuscular volume.
Missing, 9737.
Missing, 27 780.
Missing, 12 864.
Characteristics for all Adult Hospitalized COVID-19 Patients by Anticoagulation Status
| Characteristic . | Overall . | No Anticoagulation . | Prophylaxis . | Therapeutic . |
|---|---|---|---|---|
| Total population, No. | 162 842 | 58 675 | 65 256 | 38 911 |
| Demographics | ||||
| Age, y, mean (SD) | 56 (19) | 49 (20) | 58 (18) | 61 (17) |
| Male sex | 79 401 (49) | 24 895 (42) | 32 532 (50) | 21 974 (56) |
| Race and ethnicitya | ||||
| Asian | 5356 (3.5) | 1706 (3.1) | 2412 (3.9) | 1238 (3.4) |
| Hispanic or Latino | 33 713 (22) | 12 076 (22) | 13 785 (22) | 7852 (22) |
| Native Hawaiian or other Pacific Islander | 251 (0.2) | 88 (0.2) | 116 (0.2) | 47 (0.1) |
| Non-Hispanic black | 36 957 (24) | 14 933 (27) | 13 074 (21) | 8950 (25) |
| Non-Hispanic white | 75 948 (50) | 25 775 (47) | 31 974 (52) | 18 199 (50) |
| Other | 880 (0.6) | 303 (0.6) | 362 (0.6) | 215 (0.6) |
| Regionb | ||||
| Midwest | 47 430 (35) | 17 136 (36) | 19 348 (37) | 10 946 (32) |
| Northeast | 33 278 (25) | 11 242 (23) | 12 407 (24) | 9629 (28) |
| South | 36 797 (27) | 14 715 (31) | 13 083 (25) | 8999 (26) |
| West | 17 557 (13) | 5087 (11) | 7902 (15) | 4568 (13) |
| Length of stay, d, mean (SD) | 9 (13) | 5 (9) | 9 (12) | 13 (16) |
| Comorbidities | ||||
| BMI, kg/m2, mean (SD)c | 31 (9) | 30 (8) | 31 (9) | 32 (9) |
| Charlson Comorbidity Index, mean (SD) | 1 (2) | 1 (2) | 1 (2) | 1 (2) |
| Cancer | 10 733 (6.6) | 3563 (6.1) | 4488 (6.9) | 2682 (6.9) |
| Chronic pulmonary disease | 21 046 (13) | 6972 (12) | 9247 (14) | 4827 (12) |
| Congestive heart failure | 9455 (5.8) | 2842 (4.8) | 3893 (6.0) | 2720 (7.0) |
| Dementia | 3527 (2.2) | 896 (1.5) | 1865 (2.9) | 766 (2.0) |
| Diabetes mellitus with complications | 11 884 (7.3) | 3573 (6.1) | 5269 (8.1) | 3042 (7.8) |
| Diabetes mellitus | 27 760 (17) | 7910 (13) | 12 711 (19) | 7139 (18) |
| HIV | 830 (0.5) | 348 (0.6) | 339 (0.5) | 143 (0.4) |
| Liver disease, mild | 7790 (4.8) | 2830 (4.8) | 3366 (5.2) | 1594 (4.1) |
| Liver disease, severe | 1384 (0.8) | 620 (1.1) | 523 (0.8) | 241 (0.6) |
| Metastases | 2281 (1.4) | 770 (1.3) | 909 (1.4) | 602 (1.5) |
| Myocardial infarction | 4615 (2.8) | 1282 (2.2) | 2096 (3.2) | 1237 (3.2) |
| Paralysis | 849 (0.5) | 258 (0.4) | 401 (0.6) | 190 (0.5) |
| Peptic ulcer disease | 1544 (0.9) | 571 (1.0) | 663 (1.0) | 310 (0.8) |
| Peripheral vascular disease | 8580 (5.3) | 2686 (4.6) | 3674 (5.6) | 2220 (5.7) |
| Renal disease | 13 898 (8.5) | 4815 (8.2) | 5630 (8.6) | 3453 (8.9) |
| Rheumatologic disease | 4836 (3.0) | 1511 (2.6) | 2179 (3.3) | 1146 (2.9) |
| Laboratory tests, mean (SD) | ||||
| CBC | ||||
| Hemoglobin, g/dL | 13.04 (2.21) | 12.69 (2.32) | 13.23 (2.10) | 13.17 (2.20) |
| MCV, fL | 88 (7) | 88 (7) | 88 (7) | 89 (7) |
| Platelet count, ×10E3/µL | 229 (97) | 229 (95) | 228 (96) | 232 (100) |
| Neutrophils, absolute, ×10E3/µL | 88 (7) | 88 (7) | 88 (7) | 89 (7) |
| Lymphocytes, absolute, ×10E3/µL | 1.91 (1.54) | 2.06 (2.10) | 1.76 (1.22) | 2.02 (1.47) |
| CMP | ||||
| Glucose, mg/dL | 147 (78) | 135 (74) | 148 (77) | 158 (84) |
| BUN, mg/dL | 21 (19) | 22 (22) | 20 (17) | 24 (20) |
| Creatinine, mg/dL | 1.34 (1.67) | 1.50 (2.09) | 1.22 (1.38) | 1.37 (1.54) |
| BUN/creatinine ratio | 18 (9) | 17 (9) | 18 (8) | 19 (9) |
| Albumin, g/dL | 3.53 (0.61) | 3.65 (0.67) | 3.52 (0.57) | 3.39 (0.57) |
| ALT, SGPT | 50 (163) | 49 (221) | 49 (127) | 52 (140) |
| AST, SGOT | 63 (256) | 62 (327) | 60 (188) | 69 (271) |
| Coagulation | ||||
| D-dimer, mg/L FEU | 2.11 (3.59) | 2.08 (3.90) | 1.85 (3.09) | 2.70 (4.24) |
| International Normalized Ratio | 1.20 (0.62) | 1.29 (0.95) | 1.13 (0.39) | 1.21 (0.58) |
| Fibrinogen, pg/mL | 521 (191) | 441 (188) | 531 (182) | 543 (195) |
| Inflammatory and other | ||||
| ESR, mm/h | 56 (34) | 51 (35) | 56 (33) | 58 (33) |
| IL-6, pg/mL | 96 (876) | 223 (2596) | 75 (239) | 97 (535) |
| LDH, units/L | 454 (586) | 417 (878) | 417 (356) | 533 (692) |
| Lactate, mM | 1.91 (1.54) | 2.06 (2.10) | 1.76 (1.22) | 2.02 (1.47) |
| Characteristic . | Overall . | No Anticoagulation . | Prophylaxis . | Therapeutic . |
|---|---|---|---|---|
| Total population, No. | 162 842 | 58 675 | 65 256 | 38 911 |
| Demographics | ||||
| Age, y, mean (SD) | 56 (19) | 49 (20) | 58 (18) | 61 (17) |
| Male sex | 79 401 (49) | 24 895 (42) | 32 532 (50) | 21 974 (56) |
| Race and ethnicitya | ||||
| Asian | 5356 (3.5) | 1706 (3.1) | 2412 (3.9) | 1238 (3.4) |
| Hispanic or Latino | 33 713 (22) | 12 076 (22) | 13 785 (22) | 7852 (22) |
| Native Hawaiian or other Pacific Islander | 251 (0.2) | 88 (0.2) | 116 (0.2) | 47 (0.1) |
| Non-Hispanic black | 36 957 (24) | 14 933 (27) | 13 074 (21) | 8950 (25) |
| Non-Hispanic white | 75 948 (50) | 25 775 (47) | 31 974 (52) | 18 199 (50) |
| Other | 880 (0.6) | 303 (0.6) | 362 (0.6) | 215 (0.6) |
| Regionb | ||||
| Midwest | 47 430 (35) | 17 136 (36) | 19 348 (37) | 10 946 (32) |
| Northeast | 33 278 (25) | 11 242 (23) | 12 407 (24) | 9629 (28) |
| South | 36 797 (27) | 14 715 (31) | 13 083 (25) | 8999 (26) |
| West | 17 557 (13) | 5087 (11) | 7902 (15) | 4568 (13) |
| Length of stay, d, mean (SD) | 9 (13) | 5 (9) | 9 (12) | 13 (16) |
| Comorbidities | ||||
| BMI, kg/m2, mean (SD)c | 31 (9) | 30 (8) | 31 (9) | 32 (9) |
| Charlson Comorbidity Index, mean (SD) | 1 (2) | 1 (2) | 1 (2) | 1 (2) |
| Cancer | 10 733 (6.6) | 3563 (6.1) | 4488 (6.9) | 2682 (6.9) |
| Chronic pulmonary disease | 21 046 (13) | 6972 (12) | 9247 (14) | 4827 (12) |
| Congestive heart failure | 9455 (5.8) | 2842 (4.8) | 3893 (6.0) | 2720 (7.0) |
| Dementia | 3527 (2.2) | 896 (1.5) | 1865 (2.9) | 766 (2.0) |
| Diabetes mellitus with complications | 11 884 (7.3) | 3573 (6.1) | 5269 (8.1) | 3042 (7.8) |
| Diabetes mellitus | 27 760 (17) | 7910 (13) | 12 711 (19) | 7139 (18) |
| HIV | 830 (0.5) | 348 (0.6) | 339 (0.5) | 143 (0.4) |
| Liver disease, mild | 7790 (4.8) | 2830 (4.8) | 3366 (5.2) | 1594 (4.1) |
| Liver disease, severe | 1384 (0.8) | 620 (1.1) | 523 (0.8) | 241 (0.6) |
| Metastases | 2281 (1.4) | 770 (1.3) | 909 (1.4) | 602 (1.5) |
| Myocardial infarction | 4615 (2.8) | 1282 (2.2) | 2096 (3.2) | 1237 (3.2) |
| Paralysis | 849 (0.5) | 258 (0.4) | 401 (0.6) | 190 (0.5) |
| Peptic ulcer disease | 1544 (0.9) | 571 (1.0) | 663 (1.0) | 310 (0.8) |
| Peripheral vascular disease | 8580 (5.3) | 2686 (4.6) | 3674 (5.6) | 2220 (5.7) |
| Renal disease | 13 898 (8.5) | 4815 (8.2) | 5630 (8.6) | 3453 (8.9) |
| Rheumatologic disease | 4836 (3.0) | 1511 (2.6) | 2179 (3.3) | 1146 (2.9) |
| Laboratory tests, mean (SD) | ||||
| CBC | ||||
| Hemoglobin, g/dL | 13.04 (2.21) | 12.69 (2.32) | 13.23 (2.10) | 13.17 (2.20) |
| MCV, fL | 88 (7) | 88 (7) | 88 (7) | 89 (7) |
| Platelet count, ×10E3/µL | 229 (97) | 229 (95) | 228 (96) | 232 (100) |
| Neutrophils, absolute, ×10E3/µL | 88 (7) | 88 (7) | 88 (7) | 89 (7) |
| Lymphocytes, absolute, ×10E3/µL | 1.91 (1.54) | 2.06 (2.10) | 1.76 (1.22) | 2.02 (1.47) |
| CMP | ||||
| Glucose, mg/dL | 147 (78) | 135 (74) | 148 (77) | 158 (84) |
| BUN, mg/dL | 21 (19) | 22 (22) | 20 (17) | 24 (20) |
| Creatinine, mg/dL | 1.34 (1.67) | 1.50 (2.09) | 1.22 (1.38) | 1.37 (1.54) |
| BUN/creatinine ratio | 18 (9) | 17 (9) | 18 (8) | 19 (9) |
| Albumin, g/dL | 3.53 (0.61) | 3.65 (0.67) | 3.52 (0.57) | 3.39 (0.57) |
| ALT, SGPT | 50 (163) | 49 (221) | 49 (127) | 52 (140) |
| AST, SGOT | 63 (256) | 62 (327) | 60 (188) | 69 (271) |
| Coagulation | ||||
| D-dimer, mg/L FEU | 2.11 (3.59) | 2.08 (3.90) | 1.85 (3.09) | 2.70 (4.24) |
| International Normalized Ratio | 1.20 (0.62) | 1.29 (0.95) | 1.13 (0.39) | 1.21 (0.58) |
| Fibrinogen, pg/mL | 521 (191) | 441 (188) | 531 (182) | 543 (195) |
| Inflammatory and other | ||||
| ESR, mm/h | 56 (34) | 51 (35) | 56 (33) | 58 (33) |
| IL-6, pg/mL | 96 (876) | 223 (2596) | 75 (239) | 97 (535) |
| LDH, units/L | 454 (586) | 417 (878) | 417 (356) | 533 (692) |
| Lactate, mM | 1.91 (1.54) | 2.06 (2.10) | 1.76 (1.22) | 2.02 (1.47) |
Continuous variables presented as mean (standard deviation), as indicated, and categorical variables as frequency, No. (%).
Abbreviations: ALT, SGPT, alanine aminotransferase, serum glutamic-pyruvic transaminase; AST, SGOT, aspartate aminotransferase, serum glutamic-oxaloacetic transaminase; BMI, body mass index; BUN, blood urea nitrogen; CBC, complete blood count; CMP, comprehensive metabolic panel; COVID-19, coronavirus disease 2019; ESR, erythrocyte sedimentation rate; FEU, fibrinogen equivalent unit; HIV, human immunodeficiency virus; IL-6, interleukin 6; LDH, lactate dehydrogenase; MCV, mean corpuscular volume.
Missing, 9737.
Missing, 27 780.
Missing, 12 864.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
